Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth
in revenues for its antiviral and
other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures
in European
countries that may increase the amount of discount required on Gilead's products; an increase
in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift
in payer mix to more highly discounted payer segments and geographic
regions and decreases
in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations
in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations
in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or
other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials
in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations
in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates
in the timelines currently anticipated; Gilead's ability to receive regulatory approvals
in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products
over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta
in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes
in its stock price, corporate or
other market conditions; fluctuations
in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and
other risks identified from time to time
in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Both imports and exports of information technology and communications (ITC) equipment have grown strongly
over recent years, with China now accounting for a larger proportion of world ITC equipment exports than any
other country in the
region except Japan.
These tables also illustrate, however, that exporters have made some gains
in sales to
other countries;
over the past year, growth
in exports of manufactures and services to many
countries outside the Asian
region have been stronger than trend growth rates recorded earlier
in the 1990s.
«The Igbo from all
over the
country and
in the Diaspora should be advised to converge
in their
region in the South - East for a plebiscite to be organized and conducted by the United Nations and
other regional bodies for them to categorically to decide between remaining part of Nigeria or having their separate
country.
Many people
in the party are yet to get
over the party's humiliating defeat
in the 2016 December general elections, and it is hoped that the unity walk — to be held
in other regions of the
country before the year ends — a recommendation made
in the Prof Kwesi Botchwey Committee report - will lift up spirits.
At the beginning of my career
in mathematical biology, I focused on forging relationships with Europe — Britain, Germany, Italy, and the Netherlands, just to name a few — but
over the last decade, I shifted gears and began to seek closer ties with mathematical biology groups
in Latin American
countries such as Mexico, Argentina, Chile, and Colombia as well as
other regions of the world.
These're - exports» from European Union
countries require
over 9 million hectares of cropland
in other regions.
Thirty years later — the equivalent of one Saturn year,
in other words, the time the planet takes to go all the way around the Sun — and
over more than six consecutive years, researchers
in the UPV / EHU's Planetary Sciences Group,
in collaboration with astronomers from various
countries, were able to observe Saturn's northern polar
region in detail once again and confirmed that the hexagon continued
in place.
One dealer contacted by Ward's expresses reservations
over the plan's timing, saying some
regions of the
country are further behind
in the economic recovery than
others.
After Huayang's extensive research
over the past six months of solar developers around the world, Huayang has chosen SkyPower, the world leading global developer of utility - scale solar energy projects, as its global partner to jointly develop and build renewable energy projects along the Belt and Road
regions as well
in other key selected
countries.
If you include
other large - scale projects such as the proposed plans to mine for shale gas
in various parts of the UK and Potash
in North Yorkshire you can see how conveyancers all
over the
country need to fully get to grips with what developments might impact their
regions.
While on one hand Tata is a leading group
in the
country specializing
in multiple business ventures, on the
other hand AIA boasts of being the largest listed pan-Asian life insurance group which has a presence
in over 17 markets
in the Asia Pacific
region.